NewsRoom Articles - Page 42 of 154 - PsychedelicNewsWire (PNW)

TuesdayDec 20, 2022 2:00 pm

Psychedelic Drug Developers to Carry Out Clinical Trials in UK

Some psychedelic medicine developers in the United States and Canada have entered into an agreement with Clerkenwell Health in order to carry out trials on their drugs for various mental health indications in the United Kingdom. Clerkenwell Health is a clinical research organization that conducts trials for therapies for a range of mental health illnesses in London. The drug developers hope to treat mental health conditions such as major depressive disorder, social anxiety, nicotine addiction and autism spectrum disorder as well as adjustment disorder for patients with diagnoses of terminal illnesses, including cancer. Data from trials conducted in the United…

MondayDec 19, 2022 11:32 am

Three Theories Explaining Causes of Depression

Researchers have spent a significant amount of time trying to figure out the mechanisms that cause depression in an effort to develop preventative and treatment strategies for the mental condition. Over decades of intense research, three theories have emerged as the most plausible. The monoamine theory posits that the depletion of key hormones such as serotonin, norepinephrine and/or dopamine was instrumental in the development of antidepressants. This theory stated that a chemical imbalance in the brain and nervous system was to blame for the development of depression. More specifically, it said that a deficiency in monoamine transmitters was the primary…

FridayDec 16, 2022 1:01 pm

Johns Hopkins Researchers Document Different Psychedelic-Induced Belief Changes

Psychedelics have become popular in the scientific community these past few years. Long prohibited by federal law, psychedelics are now enjoying a renaissance that is predicted to cause major waves in the psychiatry industry. Initial studies have found that hallucinogenic drugs such as psilocybin, MDMA and ketamine can have significant mental health benefits, especially when they are paired with psychotherapy. Over the past couple of years, the pharmaceutical industry and investors have injected millions in funding psychedelic research with the aim of developing psychedelic-assisted therapies capable of treating debilitating mental health conditions such as depression and post-traumatic stress disorder. Researchers…

ThursdayDec 15, 2022 2:01 pm

Analysis Predicts Most States Will Have Legalized Psychedelics by 2037

A new analysis carried out by researchers at Washington University in St. Louis has projected that by 203, most states will have legalized psychedelics. After Denver became the first county to decriminalize the use of psilocybin in 2019, many other counties and even states have followed suit. For instance, the state of Oregon approved ballot measures that not only promoted research into psychedelics but also ended the substances’ criminalization and legalized their therapeutic use. In November, the state of Colorado legalized the possession of an extensive range of psychedelics after a ballot measure with this provision was approved by its…

WednesdayDec 14, 2022 1:35 pm

Longevity Science Foundation Announces Funding for Longevity, Psychedelics Grant Proposals

The Longevity Science Foundation has pledged to give $1 billion in funding over the next decade to projects, institutions and studies that advance healthy human longevity. The foundation, which is a nonprofit membership organization that is focused on advancing the field of human longevity by funding the research and development of medical technologies to extend the healthy human lifespan, is calling for proposals in longevity, psychedelics and aging clocks. Numerous studies have found that psychedelics such as psilocybin, MDMA and ketamine may be useful in the treatment of mental health conditions, including addiction, depression and post-traumatic stress disorder. With regard…

TuesdayDec 13, 2022 1:17 pm

US Doctors Could Prescribe MDMA in 2024

MDMA is a stimulant drug that causes hallucinations. Researchers have found that the drug, which is also known as ecstasy or molly, may be useful in the treatment of a range of mental health conditions, including anxiety. A recently conducted medical trial also found that the drug, which is popular in rave culture, could effectively treat post-traumatic stress disorder. Post-traumatic stress disorder is a mental health condition that’s usually triggered when an individual witnesses or experiences a traumatic event. Symptoms may include nightmares, flashbacks and severe anxiety, among other things. The trial was carried out by Multidisciplinary Association for Psychedelic…

MondayDec 12, 2022 2:18 pm

Research Shows LSD Microdosing Increases Reward-Related Activity in the Brain

A new study has found that microdosing on LSD may increase reward-related activity in the human brain. Microdosing involves ingesting small doses of a psychedelic such as LSD on a regular basis. The practice has increased in popularity these past few years, with many viewing it as a way to improve creativity, productivity and psychological well-being. However, there is scant scientific evidence supporting the practice’s benefits. The researchers’ objective was to find out whether LSD could change the signature response of the brain to a rewarding stimulus when it was administered in low doses. The study was led by Professor…

FridayDec 09, 2022 11:13 am

What Investors Should Know About Psychedelics Clinical Trials

Psychedelics are among the hottest things on the market right now. As more and more studies have indicated that these hallucinogenic drugs can have significant mental health benefits, especially when paired with psychotherapy, interest in psychedelic research has increased significantly. Scientists from around the world are now preparing or already running studies to determine the efficacy of psychedelics such as psilocybin and LSD against mental health conditions such as post-traumatic stress disorder, depression and eating disorders. With the psychedelics drugs market projected to be worth $10.75 billion by 2027, plenty of individual and institutional investors are looking to buy in…

ThursdayDec 08, 2022 12:33 pm

Does VR Have a Place in Psychedelic Therapy?

Interest in psychedelic-assisted therapies has blown up over the past couple of years amid surging interest in psychedelic medications across the mainstream and scientific communities. As America’s mental health crisis has grown, there has been increased interest in alternative treatments that do not have the usual side effects associated with typical pharmaceutical drugs. Psychedelics, long enjoyed in certain circles for their hallucinogenic effects, are now being studied for their potential mental health benefits. Early research reveals that drugs such as psilocybin and ketamine can effectively treat mental health conditions, including depression, PTSD and eating disorders, with minimal side effects. Now,…

WednesdayDec 07, 2022 2:00 pm

DEA Increases Final 2023 Production Quotas for Psychedelics

Recently, the Drug Enforcement Administration (DEA) released its latest quotas for the production for drugs to be used in research next year. The agency’s final quotas show even higher limits for the manufacture of psychedelics such as 5-MeO-DMT, psilocin and MDMA. The figures are even higher than the quotas the agency had earlier proposed last month. The DEA expanded specific quotas even more after considering recommendations made by the public. For instance, the Drug Enforcement Administration set its new psilocin target at 12,000 grams. This is more than double the 2022 production quota of the compound, which is extracted from…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000